Compass Therapeutics (CMPX) Competitors $1.75 +0.05 (+2.94%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.77 +0.02 (+1.14%) As of 04/17/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. DYN, GPCR, ETNB, CMRX, CDMO, RCUS, VIR, MLYS, PAHC, and SYREShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Vir Biotechnology Mineralys Therapeutics Phibro Animal Health Spyre Therapeutics Compass Therapeutics (NASDAQ:CMPX) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation. Is CMPX or DYN more profitable? Compass Therapeutics' return on equity of -32.37% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -32.37% -30.67% Dyne Therapeutics N/A -57.46%-51.62% Do analysts rate CMPX or DYN? Compass Therapeutics presently has a consensus price target of $13.38, suggesting a potential upside of 664.29%. Dyne Therapeutics has a consensus price target of $47.46, suggesting a potential upside of 480.92%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Compass Therapeutics is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Do insiders & institutionals have more ownership in CMPX or DYN? 68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 28.5% of Compass Therapeutics shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, CMPX or DYN? Compass Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Does the media refer more to CMPX or DYN? In the previous week, Dyne Therapeutics had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 8 mentions for Dyne Therapeutics and 3 mentions for Compass Therapeutics. Dyne Therapeutics' average media sentiment score of 0.47 beat Compass Therapeutics' score of 0.13 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in CMPX or DYN? Dyne Therapeutics received 1 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 79.63% of users gave Compass Therapeutics an outperform vote while only 77.19% of users gave Dyne Therapeutics an outperform vote. CompanyUnderperformOutperformCompass TherapeuticsOutperform Votes4379.63% Underperform Votes1120.37% Dyne TherapeuticsOutperform Votes4477.19% Underperform Votes1322.81% Which has stronger earnings & valuation, CMPX or DYN? Compass Therapeutics has higher revenue and earnings than Dyne Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K284.70-$42.49M-$0.37-4.73Dyne TherapeuticsN/AN/A-$235.94M-$3.35-2.44 SummaryCompass Therapeutics beats Dyne Therapeutics on 10 of the 17 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.00M$2.84B$5.29B$7.35BDividend YieldN/A1.87%5.12%4.31%P/E Ratio-4.7330.4821.7317.77Price / Sales284.70441.91379.1697.65Price / CashN/A168.6838.2234.64Price / Book1.503.466.443.98Net Income-$42.49M-$72.06M$3.21B$247.44M7 Day Performance3.24%2.52%2.82%1.82%1 Month Performance-24.24%-15.73%-8.67%-6.98%1 Year Performance17.45%-26.11%11.32%1.49% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics3.3573 of 5 stars$1.75+2.9%$13.38+664.3%+14.4%$242.00M$850,000.00-4.7320Short Interest ↑Gap DownDYNDyne Therapeutics3.5447 of 5 stars$7.49-9.5%$47.46+533.7%-67.1%$847.28MN/A-2.10100GPCRStructure Therapeutics2.5906 of 5 stars$14.31-5.4%$81.29+468.0%-41.3%$820.58MN/A-19.34136News CoverageGap UpETNB89bio2.5768 of 5 stars$5.49-4.9%$27.56+401.9%-33.8%$801.45MN/A-1.8940Short Interest ↑High Trading VolumeCMRXChimerix2.7747 of 5 stars$8.52-0.1%$8.53+0.2%+844.7%$799.21M$212,000.00-9.0690Analyst ForecastNews CoverageCDMOAvid Bioservices0.8311 of 5 stars$12.50+0.1%$12.25-2.0%+86.2%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading VolumeRCUSArcus Biosciences2.3869 of 5 stars$7.28+5.9%$30.25+315.8%-46.8%$764.88M$258M-2.31500Positive NewsHigh Trading VolumeVIRVir Biotechnology2.5104 of 5 stars$5.52-1.1%$35.67+546.1%-33.3%$757.03M$63.71M-1.41580Analyst ForecastShort Interest ↑MLYSMineralys Therapeutics2.5505 of 5 stars$12.05-2.8%$33.00+173.9%+11.3%$756.56MN/A-3.3128Insider TradeShort Interest ↑News CoverageHigh Trading VolumePAHCPhibro Animal Health3.9398 of 5 stars$18.66-2.8%$21.00+12.5%+34.3%$755.79M$1.11B38.881,860Analyst ForecastNews CoveragePositive NewsSYRESpyre Therapeutics1.8238 of 5 stars$12.39-3.1%$50.33+306.2%-63.1%$746.58M$890,000.00-1.66100High Trading Volume Related Companies and Tools Related Companies DYN Alternatives GPCR Alternatives ETNB Alternatives CMRX Alternatives CDMO Alternatives RCUS Alternatives VIR Alternatives MLYS Alternatives PAHC Alternatives SYRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMPX Stock Free CMPX Stock Alerts